Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             290 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer Iaffaioli, R.V.
 1996
 32 Supplement 1 p. 1901-1904
4 p.
 artikel
2 Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study Gatzemeier, U.
 1996
 32 Supplement 1 p. 243-248
6 p.
 artikel
3 Activity of gemcitabine in platinum-resistant ovarian germ cell cancer Maas, K.
 1996
 32 Supplement 1 p. 1437-1438
2 p.
 artikel
4 A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy 1996
 32 Supplement 1 p. 807-813
7 p.
 artikel
5 Alcohol and breast cancer in the Swiss Canton of Vaud Levi, F.
 1996
 32 Supplement 1 p. 2108-2113
6 p.
 artikel
6 Amifostine (Ethyol®): Pharmacokinetic and Pharmacodynamic Effects in vivo Vijgh, W.J.F. van der
 1996
 32 Supplement 1 p. S26-S30
5 p.
 artikel
7 An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer? Chapman, J.W.
 1996
 32 Supplement 1 p. 1949-1956
8 p.
 artikel
8 An increased loading dose of ondansetron: a North European, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2 Brock, P.
 1996
 32 Supplement 1 p. 1744-1748
5 p.
 artikel
9 An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor Bretti, S.
 1996
 32 Supplement 1 p. 1171-1178
8 p.
 artikel
10 An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens Martoni, A.
 1996
 32 Supplement 1 p. 82-85
4 p.
 artikel
11 Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification Wärri, A.M.
 1996
 32 Supplement 1 p. 134-140
7 p.
 artikel
12 Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin Scambia, G.
 1996
 32 Supplement 1 p. 877-882
6 p.
 artikel
13 Antitopoisomerase drug action and resistance Nitiss, J.L.
 1996
 32 Supplement 1 p. 958-966
9 p.
 artikel
14 A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma Proebstle, T.M.
 1996
 32 Supplement 1 p. 1530-1533
4 p.
 artikel
15 A Phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer Ychou, M.
 1996
 32 Supplement 1 p. 1933-1937
5 p.
 artikel
16 A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines Fountzilas, G.
 1996
 32 Supplement 1 p. 47-51
5 p.
 artikel
17 A randomised study comparing granulocyte-coiony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy Sanchiz, F.
 1996
 32 Supplement 1 p. 52-56
5 p.
 artikel
18 A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer * Jonat, W.
 1996
 32 Supplement 1 p. 404-412
 artikel
19 A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb Lingam, M.K.
 1996
 32 Supplement 1 p. 1668-1673
6 p.
 artikel
20 Attitudes toward informing the cancer patient—A survey of Norwegian physicians Loge, J.H.
 1996
 32 Supplement 1 p. 1344-1348
5 p.
 artikel
21 Augmented expression of LCK message directed from the downstream promoter in human colorectal cancer specimens Nakamura, K.
 1996
 32 Supplement 1 p. 1401-1407
7 p.
 artikel
22 Autologous bone marrow transplantation for uterine sarcoma. Case report Recchia, F.
 1996
 32 Supplement 1 p. 553-554
 artikel
23 Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: In vitro synergistic cytotoxicity and dna-induced strand-breaks Andreuccetti, M.
 1996
 32 Supplement 1 p. 1219-1226
8 p.
 artikel
24 Breast cancer prevention trial needs 3000 fewer women than planned 1996
 32 Supplement 1 p. 2188-
1 p.
 artikel
25 Calendar of forthcoming meetings 1996
 32 Supplement 1 p. I-IV
nvt p.
 artikel
26 Cancer and the mind—do we still believe Galen? Stiefel, F.
 1996
 32 Supplement 1 p. 2041-
1 p.
 artikel
27 Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines Morré, D.J.
 1996
 32 Supplement 1 p. 1995-2003
9 p.
 artikel
28 Cardiac transplantation in childhood cancer survivors in Great Britain Levitt, G.
 1996
 32 Supplement 1 p. 826-830
5 p.
 artikel
29 Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro Dorr, R.T.
 1996
 32 Supplement 1 p. S21-S25
5 p.
 artikel
30 Cisplatin combined with the new cisplatin-procaine complex dpr: In vitro and in vivo studies Viale, M.
 1996
 32 Supplement 1 p. 2327-2333
7 p.
 artikel
31 Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer Roca, E.
 1996
 32 Supplement 1 p. 429-432
 artikel
32 Complications of an implantable venous access device (Port-a-Cath®) during intermittent continuous infusion of chemotherapy Poorter, R.L.
 1996
 32 Supplement 1 p. 2262-2266
5 p.
 artikel
33 Continuing medical education in oncology in europe Armand, J.P.
 1996
 32 Supplement 1 p. 1296-1299
4 p.
 artikel
34 Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA Proebstle, T.M.
 1996
 32 Supplement 1 p. 1664-1667
4 p.
 artikel
35 Detection of human papillomavirus DNA in laryngeal squamous cell carcinoma by polymerase chain reaction Almadori, G.
 1996
 32 Supplement 1 p. 783-788
6 p.
 artikel
36 Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells Brew, R.
 1996
 32 Supplement 1 p. 2142-2147
6 p.
 artikel
37 DI-1. Chemotherapy: Is more better? DI-1-2 No Hortobagyi, Gabriel N.
 1996
 32 Supplement 1 p. 1-
1 p.
 artikel
38 DI-1. Chemotherapy: Is more better? DI-1-1 Yes Antman, Karen H.
 1996
 32 Supplement 1 p. 1-
1 p.
 artikel
39 DI-3. Has primary chemotherapy a routine role? DI-3-1 Yes Bonadonna, G.
 1996
 32 Supplement 1 p. 1-2
2 p.
 artikel
40 DI-2. Screening, Yes or No? DI-2-1 Yes Ciatto, S.
 1996
 32 Supplement 1 p. 1-
1 p.
 artikel
41 Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? van Holten-Verzantvoort, A.T.M.
 1996
 32 Supplement 1 p. 450-454
 artikel
42 Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies Comella, P.
 1996
 32 Supplement 1 p. 1719-1726
8 p.
 artikel
43 Effect of intracellular acidity and ionomycin on apoptosis in HL-60 Cells Park, H.J.
 1996
 32 Supplement 1 p. 540-546
 artikel
44 Effects of interleukin-1α on ovarian carcinoma in patients with recurrent disease Verschraegen, C.F.
 1996
 32 Supplement 1 p. 1609-1611
3 p.
 artikel
45 Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro Seelig, M.H.
 1996
 32 Supplement 1 p. 1968-1976
9 p.
 artikel
46 Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy Currow, D.C.
 1996
 32 Supplement 1 p. 2357-2359
3 p.
 artikel
47 Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C Berger, C.
 1996
 32 Supplement 1 p. 1707-1711
5 p.
 artikel
48 EP-1 breast cancer imaging Dilhuydy, M.H.
 1996
 32 Supplement 1 p. 5-
1 p.
 artikel
49 EP-2 What the non-surgeons have to know about surgery? Mansel, R.-E.
 1996
 32 Supplement 1 p. 5-
1 p.
 artikel
50 Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect Mantovani, G.
 1996
 32 Supplement 1 p. 1983-1985
3 p.
 artikel
51 Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry Brotherick, I.
 1996
 32 Supplement 1 p. 2334-2341
8 p.
 artikel
52 Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: Association with early lymphatic spread of tumour cells Passlick, B.
 1996
 32 Supplement 1 p. 141-145
5 p.
 artikel
53 Expression of p53 protein as a prognostic factor in patients With gastric cancer Victorzon, M.
 1996
 32 Supplement 1 p. 215-220
6 p.
 artikel
54 Expression of the 67 kD Laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5 van den Brûle, F.A.
 1996
 32 Supplement 1 p. 1598-1602
5 p.
 artikel
55 Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer Schuster-Uitterhoeve, A.L.J.
 1996
 32 Supplement 1 p. 1314-1319
6 p.
 artikel
56 First Nationwide survey on Nasopharyngeal carcinoma in Finland 1996
 32 Supplement 1 p. 2190-
1 p.
 artikel
57 Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial Viscoli, C.
 1996
 32 Supplement 1 p. 814-820
7 p.
 artikel
58 Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines Zaffaroni, N.
 1996
 32 Supplement 1 p. 1766-1773
8 p.
 artikel
59 Follow-up for stage 1 teratoma surveillance patients Lander, F.
 1996
 32 Supplement 1 p. 900-901
2 p.
 artikel
60 Health-related quality of life of adults surviving malignancies in childhood Apajasalo, M.
 1996
 32 Supplement 1 p. 1354-1358
5 p.
 artikel
61 High-dose melphalan followed by autograft employing non-cryopreserved peripheral blood progenitor cells in children Jones, N.
 1996
 32 Supplement 1 p. 1938-1942
5 p.
 artikel
62 High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma Ossenkoppele, G.J.
 1996
 32 Supplement 1 p. 2058-2063
6 p.
 artikel
63 High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue Soydan, A.S.
 1996
 32 Supplement 1 p. 1781-1787
7 p.
 artikel
64 Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours von Mensdorff-Pouilly, S.
 1996
 32 Supplement 1 p. 1325-1331
7 p.
 artikel
65 Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 °C whole body hyperthermia in patients with refractory sarcoma Wiedemann, G.J.
 1996
 32 Supplement 1 p. 888-892
5 p.
 artikel
66 Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics Boddy, A.V.
 1996
 32 Supplement 1 p. 1179-1184
6 p.
 artikel
67 Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop Benraad, Th.J.
 1996
 32 Supplement 1 p. 1371-1381
11 p.
 artikel
68 Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB Fleer, E.A.M.
 1996
 32 Supplement 1 p. 506-511
 artikel
69 Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089 Vink-van Wijngaarden, T.
 1996
 32 Supplement 1 p. 842-848
7 p.
 artikel
70 In the shadow of Chernobyl—a report of the first international conference of the European Commission, Belarus, Russian federation and Ukraine on the radiological consequences of the Chernobyl accident, 18–22 march 1996, Minsk, Belarus Storm, H.H.
 1996
 32 Supplement 1 p. 1864-1865
2 p.
 artikel
71 In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin Belvedere, G.
 1996
 32 Supplement 1 p. 2011-2018
8 p.
 artikel
72 “It feels better”—measuring clinical benefit Von Hoff, D.D.
 1996
 32 Supplement 1 p. 376-377
2 p.
 artikel
73 Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution Buccheri, G.
 1996
 32 Supplement 1 p. 1135-1141
7 p.
 artikel
74 Lack of effect of corticosteroids and tamoxifen on suramin protein binding and in vitro activity Driscoll, D.L.
 1996
 32 Supplement 1 p. 311-315
5 p.
 artikel
75 Letters to the editor: Comments on a case of radiation myelopathy after 2 × 8.5 Gy for inoperable non-small cell lung cancer, Dardoufas et al., European Journal of Cancer, 31A, Nos 13/14, pp. 2418–2419, 1995 Macbeth, F.
 1996
 32 Supplement 1 p. 1616-1617
2 p.
 artikel
76 Letters to the Editor: Comments on Does Age at Last Birth Affect Breast Cancer Risk?, Hsieh et al., European Journal of Cancer, 32A, No. 1, pp. 118–121, 1996 Hsieh, C.-C.
 1996
 32 Supplement 1 p. 2030-
1 p.
 artikel
77 Letters to the Editor: Comments on Does Age at Last Birth Affect Breast Cancer Risk?, Hsieh et al., European Journal of Cancer, 32A, No. 1, pp. 118–121, 1996 Maguire, A.
 1996
 32 Supplement 1 p. 2029-2030
2 p.
 artikel
78 Letters to the Editor: Comments on Palliative Endoscopie Therapy of Rectal Carcinoma, Dohmoto et al., European Journal of Cancer, 32A, No. 1, pp. 25–29, 1996 Bosset, J.-F.
 1996
 32 Supplement 1 p. 2031-2032
2 p.
 artikel
79 Letters to the Editor: Comments on Palliative Endoscopie Therapy of Rectal Carcinoma, Dohmoto et al., European Journal of Cancer, 32A, No. 1, pp. 25–29, 1996 Glynne-Jones, R.
 1996
 32 Supplement 1 p. 2031-
1 p.
 artikel
80 Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma Penna, C.
 1996
 32 Supplement 1 p. 1117-1122
6 p.
 artikel
81 Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study Gardin, G.
 1996
 32 Supplement 1 p. 176-177
2 p.
 artikel
82 Magnetic resonance imaging: present position and future prospects Curati, W.L.
 1996
 32 Supplement 1 p. 589-592
4 p.
 artikel
83 MDR1 gene expression in solid tumours Goldstein, L.J.
 1996
 32 Supplement 1 p. 1039-1050
12 p.
 artikel
84 Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations Boos, J.
 1996
 32 Supplement 1 p. 1544-1550
7 p.
 artikel
85 Multiple forms of TGF-β 1 in breast tissues: A biologically active form of the small latent complex of TGF-β 1 Baillie, R.
 1996
 32 Supplement 1 p. 1566-1573
8 p.
 artikel
86 Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation Pihkala, J.
 1996
 32 Supplement 1 p. 97-103
7 p.
 artikel
87 Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer Sagaster, P.
 1996
 32 Supplement 1 p. 1320-1324
5 p.
 artikel
88 Newly established MST-1 tumour cell line and tumourinfiltrating lymphocyte culture from a patient with soft tissue melanoma (clear cell sarcoma) and their potential applications to patient immunotherapy Liao, S.-K.
 1996
 32 Supplement 1 p. 346-356
11 p.
 artikel
89 N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma Doz, F.
 1996
 32 Supplement 1 p. 645-649
5 p.
 artikel
90 No age limit for radical radiotherapy in head and neck tumours Pignon, T.
 1996
 32 Supplement 1 p. 2075-2081
7 p.
 artikel
91 157 O - A new approach to refractory carcinoma of the prostate: microtubular inhibition with estramustine and vinorelbin Morgia, Giuseppe
 1996
 32 Supplement 1 p. S31-
1 p.
 artikel
92 163 O - Aortic infuslon (ADM, MMC, CDDP) and stop-flow (MMC, ADM) for systemically pretreated and progresslve FLGO III c and IV ovarian cancer-45 patients Gailhofer, S.
 1996
 32 Supplement 1 p. S32-
1 p.
 artikel
93 122 O - A phase I trial of epirubicin (E) and paclitaxel (P) in patients with metastatic breast cancer (MBC) Salyadori, R.
 1996
 32 Supplement 1 p. S24-
1 p.
 artikel
94 177 O - A prospective randomized trial on neoadjuvant and adjuvant chemo- and radiotherapy in primarily inoperable soft tissue sarcoma Zielinski, C.C.
 1996
 32 Supplement 1 p. S35-
1 p.
 artikel
95 117 O - Axillary node sampling in breast cancer: an assessment of its efficacy Ravi Sekar, O.
 1996
 32 Supplement 1 p. S23-
1 p.
 artikel
96 138 O - Detection of colorectal carcinoma metastases in blood Denis, M.G.
 1996
 32 Supplement 1 p. S27-
1 p.
 artikel
97 147 O - Effect of preoperative hyperthermia with radio-chemo-therapy on resectability of locally advanced rectal cancer. A phase II clinical Rau, B.
 1996
 32 Supplement 1 p. S28-
1 p.
 artikel
98 1 O - Experimental malignant conversion of early stage human melanoma cells: evidence for a dominant phenotype Bani, M.R.
 1996
 32 Supplement 1 p. S1-
1 p.
 artikel
99 69 O - Idarubicin vs mitoxantrone in a continous-infusion cyclophosphamide plus dexamethasone regimen for adyanced refractory myeloma Nozzoli, C.
 1996
 32 Supplement 1 p. S14-
1 p.
 artikel
100 143 O - Inoperable liver metastases from colo-rectal cancer treated by systemic or loco-regional chemotherapy Massidda, B.
 1996
 32 Supplement 1 p. S28-
1 p.
 artikel
101 6 O - Intrinsic multidrug resistance-associated protein in human malignant melanoma cell lines Hauptmann, E.
 1996
 32 Supplement 1 p. S2-
1 p.
 artikel
102 68 O - Maintenance low-dose (LD) oral idarubicin (oIDA) in elderly patients (pts) with acute myelogeneous leukemia (AML) Musso, M.
 1996
 32 Supplement 1 p. S14-
1 p.
 artikel
103 173 O - Management of clinically positive axillary or inguinal lymph nodes in patients with malignant melanoma-A decision analysis Kittler, H.
 1996
 32 Supplement 1 p. S35-
1 p.
 artikel
104 14 O - New mutation in BRCA 1 gene detected in 3 austrian HBOC families Wagner, T.
 1996
 32 Supplement 1 p. S3-
1 p.
 artikel
105 20 O - Oxaliplatin (L-OHP) in fluorouracil (FU) refractory patients with metastallc colorectal cancer Nolè, F.
 1996
 32 Supplement 1 p. S5-
1 p.
 artikel
106 133 O - Prognostic significance of the nm23-H1 protein expression in colorectal cancer Abad, A.
 1996
 32 Supplement 1 p. S26-
1 p.
 artikel
107 158 O - PSA doubling time after brachytherapy with I-125 for prostatic carcinoma category T1c-3G1-3N0M0 Schipper, R.A.
 1996
 32 Supplement 1 p. S31-
1 p.
 artikel
108 17 O - Role of antiestrogens as antifribotic agents Cagini, L.
 1996
 32 Supplement 1 p. S4-
1 p.
 artikel
109 58 O - Successful engraftment of t-cell-depleted HLA-incompatible transplants Aversa, F.
 1996
 32 Supplement 1 p. S12-
1 p.
 artikel
110 98 O - Tamoxifen +/- short-term chemotherapy in the treatment of node positive, hormone receptor positive breast cancer: 7-year results of a randomized trial including 517 patients Jakesz, R.
 1996
 32 Supplement 1 p. S20-
1 p.
 artikel
111 51 O The alpi trial: a randomized study of adjuvant chemotherapy for stage I-II-IIIA non-small cell lung cancer (NSCLC) Scagliotti, G.
 1996
 32 Supplement 1 p. S10-
1 p.
 artikel
112 46 O - The role of vats (videothoracoscopy) in the staging of lung cancer Manzini, L.
 1996
 32 Supplement 1 p. S9-
1 p.
 artikel
113 134 O - The S.M.A.C. study: large scale collaborative trial of adjuvant therapy in colon cancer Alexanian, A.
 1996
 32 Supplement 1 p. S26-
1 p.
 artikel
114 161 O - Very high-dose chemotherapy (VHDCT) with ematologic support in previously untreated advanced ovarian cancer (OVCA): preliminary results of a phase I-II study Benedetti-panici, P.
 1996
 32 Supplement 1 p. S32-
1 p.
 artikel
115 183 P - Age and LDH are independent prognostic factors also in HIV-related non-hodgkin's lymphoma (HIV-NHL): a monoinstitutional study of 96 patients (pts) Vaccher, E.
 1996
 32 Supplement 1 p. S38-
1 p.
 artikel
116 Pain and discomfort during mammography Aro, A.R.
 1996
 32 Supplement 1 p. 1674-1679
6 p.
 artikel
117 36 P A phase II study of epirubicin in combination therapy of small cell lung cancer (SCLC) Damianov, D.
 1996
 32 Supplement 1 p. S8-
1 p.
 artikel
118 178 P - A randomized trial of adjuvant treatment of soft tissue sarcomas by either radiotherapy or radiotherapy + ifosfamide, adriblastin and DTIC (IFADIC) intensified by the use of G-CSF Zielinski, C.
 1996
 32 Supplement 1 p. S36-
1 p.
 artikel
119 78 P - A retrospective analysis of 34 patients with primary gastrointestinal non-hodgkin's lymphoma Szabó, F.
 1996
 32 Supplement 1 p. S15-
1 p.
 artikel
120 90 P - Association Of Lactosamine Type 2 Oligosaccharide Structures with MUC-1 Apomucin in the Human Breast Cancer Cell Line SKBR5 Dettke, M.
 1996
 32 Supplement 1 p. S18-
1 p.
 artikel
121 87 P - Biological indications to surgical treatment for early breast cancer Zanon, C.
 1996
 32 Supplement 1 p. S18-
1 p.
 artikel
122 34 P - Blood vessel invasion by tumor cells and tumor angiogenesis could predict recurrence in resected non shall cell lung cancer Chiesa, G.
 1996
 32 Supplement 1 p. S7-
1 p.
 artikel
123 109 P - Brachytherapy for Breast Cancer špikalovas, V.
 1996
 32 Supplement 1 p. S22-
1 p.
 artikel
124 125 P - Breast cancer patients generalized at diagnosis have a significantly better response to polychemotherapy than those with relapse after curative surgery Steger, G.G.
 1996
 32 Supplement 1 p. S24-
1 p.
 artikel
125 88 P - Carboplatin, Etoposide Plus UFT Modulated By Orally Leucovorin Low Dose Schedule (FLEE) In Metastatic Breast Cancer (MBE) Danlels, M.
 1996
 32 Supplement 1 p. S18-
1 p.
 artikel
126 102 P - CEF ± G-CSF As primary chemotherapy (PCT) in ≥ 3cm breast cancer (BC) patients(PTS) Conti, F.
 1996
 32 Supplement 1 p. S20-
1 p.
 artikel
127 165 P - Chemotherapy in adyanced oyarian cancer Płuzańska, A.
 1996
 32 Supplement 1 p. S33-
1 p.
 artikel
128 16 P Chemotherapy induced emesis. management of early and delayed emesis in milder emetogenic regimens Barrenetxea, G.
 1996
 32 Supplement 1 p. S4-
1 p.
 artikel
129 62 P - CIP regimen as consolidation therapy after P-VABEC in aggressive NHL of the elderly Caracciolo, F.
 1996
 32 Supplement 1 p. S13-
1 p.
 artikel
130 180 P - Clinico-pathologic correlations in 120 patients (PTS) with HIV-related-systemicnon-hodgkin's lymphoma (HIV-NHL): A monoinstitutional study Nasti, G.
 1996
 32 Supplement 1 p. S37-
1 p.
 artikel
131 144 P - Colonoscopic characteristics of synchronious colorectal carcinomas Nagorni, A.
 1996
 32 Supplement 1 p. S28-
1 p.
 artikel
132 131 P - Combination of cisplatin, epirubicin and ftorafur for breast cancer Zagrekova, E.
 1996
 32 Supplement 1 p. S25-
1 p.
 artikel
133 139 P - Combined radiochemotherapy in patients with locally advanced pancreatic cancer (PC) Hejna, M.
 1996
 32 Supplement 1 p. S27-
1 p.
 artikel
134 38 P - Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumor markers in lung cancer Huang, Ming-Shyan
 1996
 32 Supplement 1 p. S8-
1 p.
 artikel
135 182 P - Epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy (CT) in combination with antiretroviral therapy and primary use of G-CSF for patients (pts) with hodgkin's disease and HIV infection (HD-HIV) Tirelli, U.
 1996
 32 Supplement 1 p. S37-
1 p.
 artikel
136 81 P - Epirubicin (EPI) + navelbine (NVB) as first line chemotherapy in advanced breast cancer (ABC) patients (PTS): a multicentric phase II study Baldini, E.
 1996
 32 Supplement 1 p. S17-
1 p.
 artikel
137 128 P - Epirubicin intermediate dose plus cyclophosphamide in the treatment of metastatic breast cancer (MBC) Trotti, G.
 1996
 32 Supplement 1 p. S25-
1 p.
 artikel
138 Percentage of free serum prostate-specific antigen: A new tool in the early diagnosis of prostatic cancer Toubert, M.-E.
 1996
 32 Supplement 1 p. 2088-2093
6 p.
 artikel
139 136 P - Feasibility and activity of a 3-day pelf-like regimen in advanced gastric cancer. Preliminary data Crivellari, D.
 1996
 32 Supplement 1 p. S27-
1 p.
 artikel
140 11 P - Frequent Loss of Heterozygosity at 6q in Malignant Salivary Gland Tumors Queimado, L.
 1996
 32 Supplement 1 p. S3-
1 p.
 artikel
141 29 P - Gemcitabine: an active well tolerated drug for advanced non small cell lung cancer (NSCLC) de Braud, F.
 1996
 32 Supplement 1 p. S6-
1 p.
 artikel
142 169 P - Glutatiflon (GSH) for protection of cisplatinum (CDDP) induced neuro- and nephrotoxicity Djavanmard, M.P.
 1996
 32 Supplement 1 p. S34-
1 p.
 artikel
143 Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: A French cancer centre multicentric study Iliadis, A.
 1996
 32 Supplement 1 p. 455-460
 artikel
144 Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma Planting, A.S.T.
 1996
 32 Supplement 1 p. 2026-2028
3 p.
 artikel
145 Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer Otto, F.
 1996
 32 Supplement 1 p. 1712-1718
7 p.
 artikel
146 Phase II trial of N-(phosphonacetyl)-l-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma Wadler, S.
 1996
 32 Supplement 1 p. 1254-1256
3 p.
 artikel
147 Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9 McLeod, H.L.
 1996
 32 Supplement 1 p. 1518-1522
5 p.
 artikel
148 Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer Klaassen, U.
 1996
 32 Supplement 1 p. 547-549
 artikel
149 Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF Ford, P.A.
 1996
 32 Supplement 1 p. 631-635
5 p.
 artikel
150 53 P - Ifosfamide, cisplatin and etoposide (ICE) combination in locally advanced non small cell lung cancer (NSCLC): a phase II study Scinto, A.F.
 1996
 32 Supplement 1 p. S10-
1 p.
 artikel
151 71 P - Immune profile in chronic lymphocytic leukemia Paydas, S.
 1996
 32 Supplement 1 p. S14-
1 p.
 artikel
152 31 P - Immunolymphoscintigraphy and sentinel node biopsy in melanoma Testori, A.
 1996
 32 Supplement 1 p. S6-
1 p.
 artikel
153 12 P - Interleukin-8 (IL-8), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), soluble tnf receptors (sTNFR) 75 and 55 after BCG therapy of urothelial cancer (TCC): kinetics over 6 instillations Thalmann, G.N.
 1996
 32 Supplement 1 p. S3-
1 p.
 artikel
154 PL-1 Genetic predtsposition to breast cancer Ponder, B.A.J.
 1996
 32 Supplement 1 p. 3-
1 p.
 artikel
155 40 P - Localized malignant mesothelioma in hungary Károlyi, A.
 1996
 32 Supplement 1 p. S8-
1 p.
 artikel
156 141 P - Local recurrence after total rectal resection, mesorectum excision and coloendoanal anastomosis for treatment of low rectal cancer Leo, E.
 1996
 32 Supplement 1 p. S27-
1 p.
 artikel
157 97 P - Low dose, short-term adjuvant chemotherapy in stage I hormone receptor negative breast cancer Jakesz, R.
 1996
 32 Supplement 1 p. S20-
1 p.
 artikel
158 152 P - MDR1 transcripts do not indicate long-term prognosis in primary colorectal carcinomas Zöchbauer, S.
 1996
 32 Supplement 1 p. S29-
1 p.
 artikel
159 176 P - Measurement of stress dimension in cancer patients Siwek, B.
 1996
 32 Supplement 1 p. S35-
1 p.
 artikel
160 52 P - Mitomycin C. vlnorelbine. carboplatin and Gm-CSF for treatment of advanced non small cell lung carcinoma (NSCLC) Schenk, T.
 1996
 32 Supplement 1 p. S10-
1 p.
 artikel
161 72 P - Modified C/MOPP-A/EBV in HD patients Płuż;ańska, A.
 1996
 32 Supplement 1 p. S14-
1 p.
 artikel
162 85 P - Modulation of decreased adhesion molecule expression on breast cancer cell lines in vitro Budinsky, A.C.
 1996
 32 Supplement 1 p. S18-
1 p.
 artikel
163 92 P - MRP and MDR1 Gene expression in primary breast carcinomas Filipits, M.
 1996
 32 Supplement 1 p. S19-
1 p.
 artikel
164 Polymorphisms in P21 CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours Milner, B.J.
 1996
 32 Supplement 1 p. 2360-2363
4 p.
 artikel
165 13 P - Ontogeny of human natural killer (NK) cells: cytolytic mechanisms Vaz, F.
 1996
 32 Supplement 1 p. S3-
1 p.
 artikel
166 73 P - Oral idarubicin (OIDA) in elderly patients (pts) with acute myelogenous Leukemia (AML): An opportunity? Visentin, F.C.A.
 1996
 32 Supplement 1 p. S14-
1 p.
 artikel
167 PP-1-7 Accumulation of TP53 as predictor of response to chemotherapy of recurrent breast cancer Berns, P.M.J.J.
 1996
 32 Supplement 1 p. 11-
1 p.
 artikel
168 43 P - Paclitaxel/cisplatin in stage IIIB/IV non-small-cell lung cancer Krajnik, G.
 1996
 32 Supplement 1 p. S9-
1 p.
 artikel
169 94 P - Paclitaxel containing high-dose chemotherapy and autologous blood stem cell support for high risk primary breast cancer Greinix, H.T.
 1996
 32 Supplement 1 p. S19-
1 p.
 artikel
170 PP-1-16 Apoptosis-loss and expression of death-related genes in breast carcinomas Sierra, A.
 1996
 32 Supplement 1 p. 12-13
2 p.
 artikel
171 45 P - Parameters of immunological response in lung cancer patients Swierkocki, K.
 1996
 32 Supplement 1 p. S9-
1 p.
 artikel
172 PP-2-26 Axillary lymphadenectomy without drainage Garbay, J.R.
 1996
 32 Supplement 1 p. 19-
1 p.
 artikel
173 PP-1-13 Breast cancer cell mediated control of human stromelysin 3 (ST3) promoter activity Ahmad, A.
 1996
 32 Supplement 1 p. 12-
1 p.
 artikel
174 PP-4-35 Breast screening for women aged < 50 — results from a family history clinic Kollias, J.
 1996
 32 Supplement 1 p. 33-
1 p.
 artikel
175 PP-1-12 Chemotherapy-induced diversification of DNA profiles in breast cancer Zaloudik, J.
 1996
 32 Supplement 1 p. 12-
1 p.
 artikel
176 PP-1-17 Circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in the diagnosis breast cancer recurrence after surgery: 5-Year results Zamagni, C.
 1996
 32 Supplement 1 p. 13-
1 p.
 artikel
177 PP-9-14 Clinical significance of pyrimidine nucleoside phosphorytese staining in breast cancer Tanaka, S.
 1996
 32 Supplement 1 p. 57-
1 p.
 artikel
178 PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881) Klijn, J.G.M.
 1996
 32 Supplement 1 p. 49-
1 p.
 artikel
179 PP-10-1 Communicating the results of breast biopsies over the telephone and in person. Is there a difference? Campbell, L.
 1996
 32 Supplement 1 p. 58-
1 p.
 artikel
180 PP-2-9 conservative approach in subareolar breast cancers: A series of 37 patients Bussières, E.
 1996
 32 Supplement 1 p. 16-
1 p.
 artikel
181 PP-1-21 Correlational study of microangiographic and immunohistochemical techniques for tumour vascularisation Dalal, A.V.
 1996
 32 Supplement 1 p. 13-
1 p.
 artikel
182 PP-1-8 Cyclin D1 expression and response to tamoxifen treatment for metastatic breast cancer Barnes, D.M.
 1996
 32 Supplement 1 p. 11-
1 p.
 artikel
183 PP-1-10 Cytogenetic analysis in short term culture of breast cancer in Korea women Bae, J.W.
 1996
 32 Supplement 1 p. 11-12
2 p.
 artikel
184 PP-1-4 Detection of isolated tumor cells in peripheral blood and bone marrow in stage I and II breast cancer Kaaresen, R.
 1996
 32 Supplement 1 p. 10-
1 p.
 artikel
185 PP-1-19 Determination of cytosol ERBB-2 protein in primary breast cancer Imoto, S.
 1996
 32 Supplement 1 p. 13-
1 p.
 artikel
186 PP-3-1 Ductal carcinoma in situ (dcis) of the breast: About 706 cases examined from 1971 to 1995 de Lara, C.Tunon
 1996
 32 Supplement 1 p. 20-
1 p.
 artikel
187 PP-8-32 EGR-R in locally advanced and inflammatory breast carcinomas Ne<sković-Konstantinović, Z.
 1996
 32 Supplement 1 p. 54-
1 p.
 artikel
188 PP-4-21 Evaluation of the european pilot project in navarra; A high breast cancer detection rate in the first round and a low rate in the second round van Marle, M.E.
 1996
 32 Supplement 1 p. 30-
1 p.
 artikel
189 PP-1-6 Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to peri-operative chemotherapy van Slooten, H.-J.
 1996
 32 Supplement 1 p. 11-
1 p.
 artikel
190 PP-1-23 Expression of thymidine phosphorylase in mammary carcinomas and its relationship to angiogenesis Yoshida, H.
 1996
 32 Supplement 1 p. 14-
1 p.
 artikel
191 PP-8-14 five-year results of a multimodal management of stage III B breast cancer Massidda, B.
 1996
 32 Supplement 1 p. 51-
1 p.
 artikel
192 170 P Phase II trial of lnterferon-γ (LFN-γ)/interleukln-2 (1L-2) for advanced renal cell carcinoma (RCC) Djavanmard, M.P.
 1996
 32 Supplement 1 p. S34-
1 p.
 artikel
193 PP-5-11 High dose mitoxantrone and cyclophosphamide with GM-CSF in first line chemotherapy of breast cancer Astone, A.
 1996
 32 Supplement 1 p. 36-
1 p.
 artikel
194 PP-9-1 Immunohistochemical analyses of proliferative activity in breast carcinomas with medullary features Jensen, V.
 1996
 32 Supplement 1 p. 55-
1 p.
 artikel
195 PP-4-1 Influence of mammographic patterns on breast cancer screening performance van Gils, C.H.
 1996
 32 Supplement 1 p. 27-
1 p.
 artikel
196 PP-1-14 Integrins αvβ1 and αvβ5 function as breast cancer cell vitronectin receptors Meyer, T.
 1996
 32 Supplement 1 p. 12-
1 p.
 artikel
197 PP-1-15 Is Cowden disease gene a tumor suppressor gene or not? Coulon, V.
 1996
 32 Supplement 1 p. 12-
1 p.
 artikel
198 101 P - Plasminogen activator inhibitor type 1 as a prognostic factor in breast cancer Fernö, Mårten
 1996
 32 Supplement 1 p. S20-
1 p.
 artikel
199 PP-2-1 Localisation of impalpable breast lesions — a surgical approach Rovere, G.Querci della
 1996
 32 Supplement 1 p. 14-
1 p.
 artikel
200 PP-3-21 loco-regional recurrences after mastectomy in breast cancer Jager, J.
 1996
 32 Supplement 1 p. 24-
1 p.
 artikel
201 PP-1-3 Luminometric immunoassays of P53 and uPA in 600 node-negative breast cancers; first evaluation of the prognostic values Peyrat, J.-Ph.
 1996
 32 Supplement 1 p. 10-
1 p.
 artikel
202 PP-1-2 Modulation of human stromelysin-3 (ST3) promoter activity by human breast cancer cell conditioned medium Ahmad, A.
 1996
 32 Supplement 1 p. 10-
1 p.
 artikel
203 PP-7-2 Neoadjuvant chemotherapy by VEC regimen in breast cancer. preliminary results of a phase II trial Dohollou, N.
 1996
 32 Supplement 1 p. 45-
1 p.
 artikel
204 PP-1-22 Non-invasive measurement of antioestrogen activity in the breast Harding, C.
 1996
 32 Supplement 1 p. 13-14
2 p.
 artikel
205 PP-7-17 Paclitaxel and carboplatin with G-CSF support in advanced breast cancer resistant to anthracyclines Aravantinos, G.
 1996
 32 Supplement 1 p. 48-
1 p.
 artikel
206 PP-7-1 phase II study of liarozole in advanced breast cancer patients 1996
 32 Supplement 1 p. 45-
1 p.
 artikel
207 PP-1-18 Plasma c-erbB2 concentrations and response to chemotherapy in breast cancer Révillion, F.
 1996
 32 Supplement 1 p. 13-
1 p.
 artikel
208 PP-1-26 Polymorphism of estrogen receptors from primary breast cancers Maaroufi, Y.
 1996
 32 Supplement 1 p. 14-
1 p.
 artikel
209 PP-1-24 Prediction of the effect of 5′-deoxy-5-fluorouridine (5′-DFUR) by the status of angiogenic enzyme thymidine phosphorylase expression in advanced breast cancer patients Tominaga, T.
 1996
 32 Supplement 1 p. 14-
1 p.
 artikel
210 PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer Rutgers, E.J.Th.
 1996
 32 Supplement 1 p. 34-
1 p.
 artikel
211 PP-6-19 Pre-Operative Diagnosis and Establishment of Breast Cancer Phenotypic Features of Prognostic Relevance on Routine Fine-Needle Cytological Samples Lesec, G.
 1996
 32 Supplement 1 p. 41-
1 p.
 artikel
212 PP-3-8 Prognosis after salvage treatment for local-regional recurrence of mastectomy or breast conservation in eortic trial 10801 van Tienhoven, G.
 1996
 32 Supplement 1 p. 21-
1 p.
 artikel
213 PP-6-9 Prognostic significance of epidermal growth factor receptor and estrogen receptor in advanced breast cancer Gaafar, R.M.
 1996
 32 Supplement 1 p. 39-40
2 p.
 artikel
214 PP-1-20 Psychosocial correlates of oestrogen and progesterone receptors in breast cancer: Results of three consecutive studies Razavi, D.
 1996
 32 Supplement 1 p. 13-
1 p.
 artikel
215 PP-1-5 Quantitative determination of c.erbB.2 oncoprotein in 1065 human breast tumours by an enzymoimmunoassay. Comparison with the clinico-biological parameters: A multicentric study Koscielny, S.
 1996
 32 Supplement 1 p. 10-11
2 p.
 artikel
216 PP-4-2 Radiation risk of mammography related to benefit in screening programs: A favourable balance? Beemsterboer, P.M.M.
 1996
 32 Supplement 1 p. 27-
1 p.
 artikel
217 60 P - Preclinical pharmacology and drug synergism studies of peg-asparaginase (PEG-ASNase) and cytarabine (ara-C) in leukemia cell lines Periclou, A.P.
 1996
 32 Supplement 1 p. S12-
1 p.
 artikel
218 PP-1-1 Refinement of the two regions on the long arm of chromosome 16 involved in breast cancer Bonnet-Dorion, F.
 1996
 32 Supplement 1 p. 10-
1 p.
 artikel
219 4 P - Prognostic value of molecular alterations of p53 and K-ras genes in non-small cell lung cancer de Anta, J.M.
 1996
 32 Supplement 1 p. S1-
1 p.
 artikel
220 PP-4-38 Screening for BRCA1 and BRCA2 Germline Mutations — Analysis of 50 Families with Clustering of Cancer Hogervorst, F.B.L.
 1996
 32 Supplement 1 p. 33-
1 p.
 artikel
221 PP-4-8 Secular trends in mortality in four large kindreds with hereditary breast-ovarian cancer Hille, E.T.M.
 1996
 32 Supplement 1 p. 28-
1 p.
 artikel
222 PP-1-25 Subclinical thyroid dysfunction in patients with breast cancer Millán, J.
 1996
 32 Supplement 1 p. 14-
1 p.
 artikel
223 PP-2-27 The organ-keeping operations in the treatment of the breast cancer T1-2 NO MO Gantsev, S.H.
 1996
 32 Supplement 1 p. 19-
1 p.
 artikel
224 PP-9-10 The prognostic significance of protein tyrosin kinase, ER, PR, and the mitotic activity index in 86 primary breast cancer patients Bayrak, J.
 1996
 32 Supplement 1 p. 57-
1 p.
 artikel
225 PP-6-1 Time since birth is a prognostic factor in primary breast cancer Kroman, Niels
 1996
 32 Supplement 1 p. 38-
1 p.
 artikel
226 PP-1-11 Transferrin receptor (cd71) expression by human breast cancer cells Artamonova, E.V.
 1996
 32 Supplement 1 p. 12-
1 p.
 artikel
227 PP-1-9 Tumor-associated lymphomonocytes from neoplastic effusions of patients with different primary tumors including breast cancers are able to release cytokines Mantovani, G.
 1996
 32 Supplement 1 p. 11-
1 p.
 artikel
228 77 P - Pulmonary impairment in long-survivors of hodgkin's disease (HD) Sorarù, M.
 1996
 32 Supplement 1 p. S15-
1 p.
 artikel
229 PP-8-12 Unclear value of salvage chemotherapy after failure to first-tine 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen for metaatatic breafit cancer Gardin, G.
 1996
 32 Supplement 1 p. 51-
1 p.
 artikel
230 2 P - Relationship between rTNF α-, Apoptosis- and Multidrug-Resistance in vitro Berger, W.
 1996
 32 Supplement 1 p. S1-
1 p.
 artikel
231 126 P - Relationships between the time of occurrence of pulmonary metastases and the volume of primary tumour in breast cancer Suwinski, R.
 1996
 32 Supplement 1 p. S24-
1 p.
 artikel
232 Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. feasibility, toxicity and long-term results of a phase II study Favaretto, A.
 1996
 32 Supplement 1 p. 2064-2069
6 p.
 artikel
233 107 P - Results of a randomized adjuvant breast cancer trial comparing a conventional with a perioperative start of chemotherapy Michl, L.
 1996
 32 Supplement 1 p. S21-
1 p.
 artikel
234 Primary gastric non-Hodgkin's lymphoma stage IE and IIE Lybeert, M.L.M.
 1996
 32 Supplement 1 p. 2306-2311
6 p.
 artikel
235 Primary Ki-1 lymphoma and the aetiology of B symptoms O'Rourke, N.
 1996
 32 Supplement 1 p. 902-903
2 p.
 artikel
236 Prognosis of patients with breast cancers up to 1 cm in diameter Fentiman, I.S.
 1996
 32 Supplement 1 p. 417-420
 artikel
237 Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma Pirisi, M.
 1996
 32 Supplement 1 p. 221-225
5 p.
 artikel
238 149 P - Role of radiotherapy (RT) in the treatment of resectable gastric cancer Skoropad, V.
 1996
 32 Supplement 1 p. S29-
1 p.
 artikel
239 179 P - Second line chemotherapy in HIV-related non-hodgkin's lymphoma: Evidence of activity of a combination of VP16, mitoxantrone and prednimustine in relapsed patients Errante, D.
 1996
 32 Supplement 1 p. S37-
1 p.
 artikel
240 27 P - Second line chemotherapy with modulation of drug resistance in patients with advanced soft tissue sarcoma Michl, I.
 1996
 32 Supplement 1 p. S6-
1 p.
 artikel
241 67 P - Second-line treament of hodgkin’ disease with abvd combination chemotherapy Monár, Zs.
 1996
 32 Supplement 1 p. S13-
1 p.
 artikel
242 93 P - Study on sentinel nodes in breast cancer using Lymphoscintigraphy and radio-guided probe Galimberti, V.
 1996
 32 Supplement 1 p. S19-
1 p.
 artikel
243 47 P - The role of basic fibroblast growth factor (bFGF) in human non small cell lung cancer (NSCLC) Mohr, Th.
 1996
 32 Supplement 1 p. S9-
1 p.
 artikel
244 99 P - Treatment of advanced breast cancer with vinorelbine (VLB), fluorouracil (FU), l-leucovorin (LLV) and human granulocyte colony-stimulating factor (GCSF) Kornek, G.V.
 1996
 32 Supplement 1 p. S20-
1 p.
 artikel
245 105 P - Two intense adjuvant regimens in high risk breast cancer patients who received neoadjuvant Massidda, B.
 1996
 32 Supplement 1 p. S21-
1 p.
 artikel
246 Quality of prostate cancer data in the Cancer Registry of Norway Harvei, S.
 1996
 32 Supplement 1 p. 104-110
7 p.
 artikel
247 Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites Boven, E.
 1996
 32 Supplement 1 p. 1382-1387
6 p.
 artikel
248 Renal function after unilateral nephrectomy for Wilms' tumour: the influence of radiation therapy de Graaf, S.S.N.
 1996
 32 Supplement 1 p. 465-469
 artikel
249 Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine 1996
 32 Supplement 1 p. 821-825
5 p.
 artikel
250 Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG study Wagener, D.J.Th.
 1996
 32 Supplement 1 p. 1310-1313
4 p.
 artikel
251 Reversion of UVC-induced tumorigenic human hybrid cells to the non-tumorigenic phenotype Sun, C.
 1996
 32 Supplement 1 p. 322-327
6 p.
 artikel
252 Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method: 115 000 screened infants in Austria Kerbl, R.
 1996
 32 Supplement 1 p. 2298-2305
8 p.
 artikel
253 Skin lesions and G-CSF in patients with malignant diseases. Malignancy or cutaneous side-effect? Loraas, A.
 1996
 32 Supplement 1 p. 554-555
 artikel
254 Somatostatin receptor imaging in small cell lung cancer Berenger, N.
 1996
 32 Supplement 1 p. 1429-1431
3 p.
 artikel
255 Spiritual healing among Norwegian hospitalised cancer patients and patients' religious needs and preferences of pastoral services Risberg, T.
 1996
 32 Supplement 1 p. 274-281
8 p.
 artikel
256 Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase iii trial Postmus, P.E.
 1996
 32 Supplement 1 p. 1498-1503
6 p.
 artikel
257 Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma Guida, M.
 1996
 32 Supplement 1 p. 730-733
4 p.
 artikel
258 Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987 Gatta, G
 1996
 32 Supplement 1 p. 831-835
5 p.
 artikel
259 Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: A decision analysis Stiggelbout, A.M.
 1996
 32 Supplement 1 p. 2267-2274
8 p.
 artikel
260 SY-9-2 Communication between Breast Cancer Patients and Physicians Fallowfield, L.J.
 1996
 32 Supplement 1 p. 44-
1 p.
 artikel
261 SY-7-1 Comparison of Technics for ER estimation Thorpe, S.
 1996
 32 Supplement 1 p. 43-
1 p.
 artikel
262 SY-1-2 Genes predisposing to breast cancer Devilee, P.
 1996
 32 Supplement 1 p. 7-
1 p.
 artikel
263 SY-6-4 hormone replacement therapy Pritchard, K.
 1996
 32 Supplement 1 p. 26-
1 p.
 artikel
264 SY-3-1 Local recurrences after breast conserving therapy: Tumor characteristics Holland, R.
 1996
 32 Supplement 1 p. 8-
1 p.
 artikel
265 SY-1-3 Loss of heterozygosity and prognosis Lidereau, Rosette
 1996
 32 Supplement 1 p. 7-
1 p.
 artikel
266 SY-8-1 New cytotoxic agents active in breast cancer (BC) Eisenhauer, E.A.
 1996
 32 Supplement 1 p. 43-
1 p.
 artikel
267 SY-9-1 Patient's Perception Thornton, H.
 1996
 32 Supplement 1 p. 44-
1 p.
 artikel
268 SY-1-4 P53 mutations and other genetic changes in invasive and intraductal breast cancer van de Vijver, M.J.
 1996
 32 Supplement 1 p. 7-
1 p.
 artikel
269 SY-4-1 proliferation markers in breast cancers Darro, F.
 1996
 32 Supplement 1 p. 25-
1 p.
 artikel
270 SY-1-1 Quality control in molecular pathology De Bortoli, Michele
 1996
 32 Supplement 1 p. 7-
1 p.
 artikel
271 SY-9-3 Quality of Life of Women in EORTC Trials Kiebert, G.M.
 1996
 32 Supplement 1 p. 44-
1 p.
 artikel
272 SY-5-1 Risk determination for good prognosis patients Namer, M.
 1996
 32 Supplement 1 p. 25-26
2 p.
 artikel
273 SY-2-1 The classification of ductal carcinoma in situ of the breast Millis, R.R.
 1996
 32 Supplement 1 p. 7-8
2 p.
 artikel
274 SY-6-1 Treatment of operable breast cancer in the elderly Fentiman, I.S.
 1996
 32 Supplement 1 p. 26-
1 p.
 artikel
275 The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers Takanami, I.
 1996
 32 Supplement 1 p. 1504-1509
6 p.
 artikel
276 The breast screening controversy Baum, M.
 1996
 32 Supplement 1 p. 9-11
3 p.
 artikel
277 The diagnostic information of tests for the detection of cancer: the usefulness of the likelihood ratio concept Giard, R.W.M.
 1996
 32 Supplement 1 p. 2042-2048
7 p.
 artikel
278 The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells in vitro Maidment, S.L.
 1996
 32 Supplement 1 p. 868-871
4 p.
 artikel
279 The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853 da Silva, F.C.
 1996
 32 Supplement 1 p. 72-77
6 p.
 artikel
280 Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy Fauser, A.A.
 1996
 32 Supplement 1 p. 1523-1529
7 p.
 artikel
281 The role of bone scintigraphy in the follow-up of osteogenic sarcoma Körholz, D.
 1996
 32 Supplement 1 p. 461-464
 artikel
282 The role of reproductive and menstrual factors in cancer of the breast before and after Menopause Talamini, R.
 1996
 32 Supplement 1 p. 303-310
8 p.
 artikel
283 Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia Buchholz, B.
 1996
 32 Supplement 1 p. 2101-2107
7 p.
 artikel
284 Treatment costs in hodgkin's disease: A cost-utility analysis Norum, J.
 1996
 32 Supplement 1 p. 1510-1517
8 p.
 artikel
285 Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects Geisler, J.
 1996
 32 Supplement 1 p. 789-792
4 p.
 artikel
286 TTF-1 gene expression in human lung tumours Fabbro, D.
 1996
 32 Supplement 1 p. 512-517
 artikel
287 Tumour necrosis factor and interferon are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells Mueller, H.
 1996
 32 Supplement 1 p. 2312-2318
7 p.
 artikel
288 Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: Correlation with soluble ICAM-1 level Viac, J.
 1996
 32 Supplement 1 p. 447-449
 artikel
289 Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts Stellmach, V.
 1996
 32 Supplement 1 p. 2394-2400
7 p.
 artikel
290 Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines Hiss, D.
 1996
 32 Supplement 1 p. 2164-2172
9 p.
 artikel
                             290 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland